• 1
    Hanahan D,Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 5770.
  • 2
    Cheng SY,Huang HJ,Nagane M,Ji XD,Wang D,Shih CC,Arap W,Huang CM,Cavenee WK. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 85027.
  • 3
    Inoue M,Hager JH,Ferrara N,Gerber HP,Hanahan D. VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis. Cancer cell 2002; 1: 193202.
  • 4
    Huang J,Frischer JS,Serur A,Kadenhe A,Yokoi A,McCrudden KW,New T,O'Toole K,Zabski S,Rudge JS,Holash J,Yancopoulos GD, et al. Regression of established tumors and metastases by potent vascular endothelial growth factor blockade. Proc Natl Acad Sci USA 2003; 100: 778590.
  • 5
    Willett CG,Boucher Y,di Tomaso E,Duda DG,Munn LL,Tong RT,Chung DC,Sahani DV,Kalva SP,Kozin SV,Mino M,Cohen KS, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 1457.
  • 6
    O'Reilly MS,Holmgren L,Chen C,Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 68992.
  • 7
    Niola F,Evangelisti C,Campagnolo L,Massalini S,Bue MC,Mangiola A,Masotti A,Maira G,Farace MG,Ciafre SA. A plasmid-encoded VEGF siRNA reduces glioblastoma angiogenesis and its combination with interleukin-4 blocks tumor growth in a xenograft mouse model. Cancer Biol Ther 2006; 5: 1749.
  • 8
    Kunkel P,Ulbricht U,Bohlen P,Brockmann MA,Fillbrandt R,Stavrou D,Westphal M,Lamszus K. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61: 66248.
  • 9
    Casanovas O,Hicklin DJ,Bergers G,Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005; 8: 299309.
  • 10
    Strieth S,Eichhorn ME,Sutter A,Jonczyk A,Berghaus A,Dellian M. Antiangiogenic combination tumor therapy blocking α(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo. Int J Cancer 2006; 119: 42331.
  • 11
    Jendreyko N,Popkov M,Rader C,Barbas CF,III. Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA 2005; 102: 82938.
  • 12
    Hopkins AL,Groom CR. The druggable genome. Nat Rev Drug Discov 2002; 1: 72730.
  • 13
    Filleur S,Courtin A,Ait-Si-Ali S,Guglielmi J,Merle C,Harel-Bellan A,Clezardin P,Cabon F. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer research 2003; 63: 391922.
  • 14
    Takei Y,Kadomatsu K,Yuzawa Y,Matsuo S,Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer research 2004; 64: 336570.
  • 15
    Wannenes F,Ciafre SA,Niola F,Frajese G,Farace MG. Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. Cancer Gene Ther 2005; 12: 92634.
  • 16
    Guan H,Zhou Z,Wang H,Jia SF,Liu W,Kleinerman ES. A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing's sarcoma growth in a xenograft mouse model. Clin Cancer Res 2005; 11: 26629.
  • 17
    Detwiller KY,Fernando NT,Segal NH,Ryeom SW,D'Amore PA,Yoon SS. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. Cancer Res 2005; 65: 58819.
  • 18
    Hagedorn M,Javerzat S,Gilges D,Meyre A,de Lafarge B,Eichmann A,Bikfalvi A. Accessing key steps of human tumor progression in vivo by using an avian embryo model. Proc Natl Acad Sci USA 2005; 102: 16438.
  • 19
    Wang X,Seed B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res 2003; 31: e154.
  • 20
    Hagedorn M,Zilberberg L,Wilting J,Canron X,Carrabba G,Giussani C,Pluderi M,Bello L,Bikfalvi A. Domain swapping in a COOH-terminal fragment of platelet factor 4 generates potent angiogenesis inhibitors. Cancer Res 2002; 62: 688490.
  • 21
    Zhang B,Kirov S,Snoddy J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res 2005; 33: W741W748.
  • 22
    Pelloski CE,Mahajan A,Maor M,Chang EL,Woo S,Gilbert M,Colman H,Yang H,Ledoux A,Blair H,Passe S,Jenkins RB, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res 2005; 11: 332634.
  • 23
    Spruance SL,Reid JE,Grace M,Samore M. Hazard ratio in clinical trials. Antimicrob Agents Chemother 2004; 48: 278792.
  • 24
    Kroemer G,Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 5139.
  • 25
    Mischel PS,Cloughesy TF,Nelson SF. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev 2004; 5: 78292.
  • 26
    Rao JS,Yamamoto M,Mohaman S,Gokaslan ZL,Fuller GN,Stetler-Stevenson WG,Rao VH,Liotta LA,Nicolson GL,Sawaya RE. Expression and localization of 92 kDa type IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis 1996; 14: 128.
  • 27
    Junker N,Johansen JS,Hansen LT,Lund EL,Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci 2005; 96: 18390.
  • 28
    Colin C,Baeza N,Bartoli C,Fina F,Eudes N,Nanni I,Martin PM,Ouafik L,Figarella-Branger D. Identification of genes differentially expressed in glioblastoma versus pilocytic astrocytoma using Suppression Subtractive Hybridization. Oncogene 2006; 25: 281826.
  • 29
    Tanwar MK,Gilbert MR,Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002; 62: 43648.
  • 30
    Lal A,Lash AE,Altschul SF,Velculescu V,Zhang L,McLendon RE,Marra MA,Prange C,Morin PJ,Polyak K,Papadopoulos N,Vogelstein B, et al. A public database for gene expression in human cancers. Cancer Res 1999; 59: 54037.
  • 31
    Hormigo A,Gu B,Karimi S,Riedel E,Panageas KS,Edgar MA,Tanwar MK,Rao JS,Fleisher M,DeAngelis LM,Holland EC. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 2006; 12: 5698704.
  • 32
    Johansen JS,Jensen BV,Roslind A,Nielsen D,Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev 2006; 15: 194202.
  • 33
    Gronlund B,Hogdall EV,Christensen IJ,Johansen JS,Norgaard-Pedersen B,Engelholm SA,Hogdall C. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int J Biol Markers 2006; 21: 1418.
  • 34
    Johansen JS,Hvolris J,Hansen M,Backer V,Lorenzen I,Price PA. Serum YKL-40 levels in healthy children and adults. Comparison with serum and synovial fluid levels of YKL-40 in patients with osteoarthritis or trauma of the knee joint. Br J Rheumatol 1996; 35: 5539.
  • 35
    Rathcke CN,Johansen JS,Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res 2006; 55: 539.
  • 36
    Pfundt R,van Ruissen F,van Vlijmen-Willems IM,Alkemade HA,Zeeuwen PL,Jap PH,Dijkman H,Fransen J,Croes H,van Erp PE,Schalkwijk J. Constitutive and inducible expression of SKALP/elafin provides anti-elastase defense in human epithelia. J Clin Invest 1996; 98: 138999.
  • 37
    Fossati G,Ricevuti G,Edwards SW,Walker C,Dalton A,Rossi ML. Neutrophil infiltration into human gliomas. Acta Neuropathologica 1999; 98: 34954.
  • 38
    Burton EC,Lamborn KR,Feuerstein BG,Prados M,Scott J,Forsyth P,Passe S,Jenkins RB,Aldape KD. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. Cancer Res 2002; 62: 620510.
  • 39
    Hidaka S,Yasutake T,Kondo M,Takeshita H,Yano H,Haseba M,Tsuji T,Sawai T,Nakagoe T,Tagawa Y. Frequent gains of 20q and losses of 18q are associated with lymph node metastasis in intestinal-type gastric cancer. Anticancer Res 2003; 23: 33537.
  • 40
    Tanner MM,Grenman S,Koul A,Johannsson O,Meltzer P,Pejovic T,Borg A,Isola JJ. Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 2000; 6: 18339.
  • 41
    Bouchard D,Morisset D,Bourbonnais Y,Tremblay GM. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol 2006; 7: 16774.
  • 42
    Iwatsuki K,Kumara E,Yoshimine T,Nakagawa H,Sato M,Hayakawa T. Elastase expression by infiltrating neutrophils in gliomas. Neurological Res 2000; 22: 4658.
  • 43
    Bingle L,Tetley TD,Bingle CD. Cytokine-mediated induction of the human elafin gene in pulmonary epithelial cells is regulated by nuclear factor-kappaB. Am J Respir Cell Mol Biol 2001; 25: 8491.
  • 44
    Tanaka N,Fujioka A,Tajima S,Ishibashi A,Hirose S. Elafin is induced in epidermis in skin disorders with dermal neutrophilic infiltration: interleukin-1 β and tumour necrosis factor-α stimulate its secretion in vitro. Br J Dermatol 2000; 143: 72832.
  • 45
    Elaraj DM,Weinreich DM,Varghese S,Puhlmann M,Hewitt SM,Carroll NM,Feldman ED,Turner EM,Alexander HR. The role of interleukin 1 in growth and metastasis of human cancer xenografts. Clin Cancer Res 2006; 12: 108896.
  • 46
    Kalinski T,Krueger S,Sel S,Werner K,Ropke M,Roessner A. ADAMTS1 is regulated by interleukin-1β, not by hypoxia, in chondrosarcoma. Hum Pathol 2007; 38: 8694
  • 47
    Luque A,Carpizo DR,Iruela-Arispe ML. ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem 2003; 278: 2365665.
  • 48
    Amano K,Okigaki M,Adachi Y,Fujiyama S,Mori Y,Kosaki A,Iwasaka T,Matsubara H. Mechanism for IL-1 β-mediated neovascularization unmasked by IL-1 β knock-out mice. J Mol Cell Cardiol 2004; 36: 46980.
  • 49
    Hochachka PW,Buck LT,Doll CJ,Land SC. Unifying theory of hypoxia tolerance: molecular/metabolic defense and rescue mechanisms for surviving oxygen lack. Proc Natl Acad Sci USA 1996; 93: 94938.
  • 50
    Said HM,Staab A,Hagemann C,Vince GH,Katzer A,Flentje M,Vordermark D. Distinct patterns of hypoxic expression of carbonic anhydrase IX (CA IX) in human malignant glioma cell lines. J Neuro-Oncol 2007; 81: 2738.
  • 51
    Lal A,Peters H,St Croix B,Haroon ZA,Dewhirst MW,Strausberg RL,Kaanders JH,van der Kogel AJ,Riggins GJ. Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 2001; 93: 133743.
  • 52
    Johansson M,Brannstrom T,Bergenheim AT,Henriksson R. Spatial expression of VEGF-A in human glioma. J Neuro-oncol 2002; 59: 16.